Semaglutide

Mechanism

Semaglutide is a GLP-1 receptor agonist — a modified version of the endogenous incretin hormone glucagon-like peptide-1, engineered with a fatty acid chain for albumin binding that extends its half-life to approximately seven days. It acts at GLP-1 receptors in the hypothalamic arcuate nucleus to suppress appetite through satiety signaling, and in the gut to slow gastric emptying, reducing the rate at which food-derived glucose enters circulation. The combined effect is sustained reduction in caloric intake driven by both reduced hunger and faster satiety per meal.

The dominant mechanism of weight loss is sustained caloric deficit via appetite suppression — semaglutide is not directly lipolytic. It does improve insulin sensitivity, and over months this improves partitioning, but if you're already eating maintenance or in surplus, the drug won't override that. The appetite signal is powerful, and clinical trial data (STEP 1–4) shows 10–15% body weight loss at 2.4 mg maintenance over 68 weeks in a population without baseline diet discipline — with active training and protein focus, outcomes are better.

Semaglutide's long half-life means a single weekly injection builds to steady-state concentration over roughly four weeks per dose level. Titration is slow by design — rushing the ramp-up amplifies nausea without improving outcomes.

Typical protocol

• Starter: 0.25 mg SC weekly × 4 weeks, then 0.5 mg × 4 weeks, then 1.0 mg × 4 weeks, then 1.7 mg × 4 weeks, then 2.4 mg maintenance. Only advance to the next dose level if the current level is well-tolerated.
• Advanced: Plateau management — if weight loss stalls at a given dose for 4+ weeks after reaching it, advance to the next tier. Some users maintain on 1.0–1.7 mg; 2.4 mg is the ceiling.
• Cycle length: Weight-loss phase can run continuously. Plan a taper before stopping — appetite rebound after abrupt cessation can be significant after 3+ months on drug.
• Reconstitution: 5 mg vial + 2.5 mL BAC water → 2 mg/mL. On a U-100 insulin syringe: 12.5 IU = 0.125 mL = 0.25 mg starting dose. 25 IU = 0.25 mL = 0.5 mg. Inject abdomen or thigh; rotate sites each week. Same day each week for consistent trough levels.

Who it's for

Fat loss goal, specifically users with significant body fat to lose who need appetite suppression to sustain a deficit over months. Works best when paired with aggressive protein intake (1 g/lb body weight minimum) and resistance training to protect lean mass. Not appropriate for lean, athletic users chasing the final few percentage points of body fat — the appetite suppression is blunt-instrument-level and the lean-mass risk at low body fat isn't worth the tool.

Stacks well with

• aod 9604 5mg — different mechanism entirely; AOD-9604 acts directly on adipocyte beta-3 receptors for lipolysis while semaglutide manages the deficit through appetite. Additive late in a cut when progress stalls.

Note: Do NOT combine with tirzepatide 5mg — redundant GLP-1 receptor targeting with amplified GI side effects and no additive benefit.

Watch-outs

• Nausea is the primary issue, front-loaded to the first 48 hours after each dose increase. It resolves as steady state is reached at that dose level. Slow titration prevents it; rushing does not.
• Slowed gastric emptying blunts post-workout nutrient delivery. Schedule carbohydrate and protein meals hours away from injection day — nutrient timing around training matters less on semaglutide but heavy peri-workout nutrition on the day of injection may sit poorly.
• Lean mass loss is the real risk. Semaglutide does not discriminate — if protein is low and training is absent, you lose muscle alongside fat. Aggressive protein and consistent resistance training are non-negotiable, not optional extras.
• Do not run this on someone already underweight or with a history of disordered eating. The appetite suppression is powerful enough to take already-compromised eating patterns somewhere dangerous.